Abstract
The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been underestimated. In Part Two of our series of reviews, we discuss the key genetic, environmental and evolutionary influences which lead to the development of these conditions, and provide a detailed account of the mechanisms by which these influences produce their effects.
Keywords: Metabolic syndrome, hypertension, obesity, insulin resistance, epidemiology, gene-environment interaction, reninangiotensin system, candidate gene approach, genome wide scanning, intermediate phenotype
Current Vascular Pharmacology
Title: The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Volume: 4 Issue: 4
Keywords: Metabolic syndrome, hypertension, obesity, insulin resistance, epidemiology, gene-environment interaction, reninangiotensin system, candidate gene approach, genome wide scanning, intermediate phenotype
Abstract: The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been underestimated. In Part Two of our series of reviews, we discuss the key genetic, environmental and evolutionary influences which lead to the development of these conditions, and provide a detailed account of the mechanisms by which these influences produce their effects.
Export Options
About this article
Cite this article as:
The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction, Current Vascular Pharmacology 2006; 4 (4) . https://dx.doi.org/10.2174/157016106778521661
DOI https://dx.doi.org/10.2174/157016106778521661 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Drugs Targeted to Improve Endothelial Function: Clinical Correlates Between Sexual and Internal Medicine (Executive Editor: Antonio Aversa)]
Current Pharmaceutical Design Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation
CNS & Neurological Disorders - Drug Targets Evaluation of General Health Status in Diabetic Patients Using Short Form Health Survey (SF-36)
Current Diabetes Reviews Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences
Current Pharmaceutical Design Severe Hyponatremia and Other Electrolyte Disturbances Associated with Indapamide
Current Drug Safety Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Editorial (Hot Topic: New Insight into the RAMP-based Family B GPCRs and their Peptide Ligands)
Current Protein & Peptide Science The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design Therapeutic Targets to Raise HDL in Patients at Risk or with Coronary Artery Disease
Current Vascular Pharmacology Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Association Between the Levels of Circulating Adhesion Molecules and Biopterins in Type-2 Diabetic Normotensive Patients Adhesion Molecules and Biopterins
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Copper Chaperone Atox1 Translocates to the Nucleus but does not Bind DNA In Vitro
Protein & Peptide Letters